Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;238(6):1237-1255.
doi: 10.1002/jcp.31034. Epub 2023 May 14.

POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes

Nikita Harish Zade  1 , Ekta Khattar  1
Affiliations
Review

POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes

Nikita Harish Zade et al. J Cell Physiol. 2023 Jun.

Abstract

The protection of telomere protein (POT1) is a telomere-binding protein and is an essential component of the six-membered shelterin complex, which is associated with the telomeres. POT1 directly binds to the 3' single-stranded telomeric overhang and prevents the activation of DNA damage response at telomeres thus preventing the telomere-telomere fusions and genomic instability. POT1 also plays a pivotal role in maintaining telomere length by regulating telomerase-mediated telomere elongation. Mutations in POT1 proteins result in three different telomere phenotypes, which include long, short, or aberrant telomere length. Long telomeres predispose individuals to cancer, while short or aberrant telomere phenotypes result in pro-aging diseases referred to as telomeropathies. Here, we review the function of POT1 proteins in telomere length hemostasis and how the spectrum of mutations reported in POT1 can be segregated toward developing very distinct disease phenotypes of cancer and telomeropathies.

Keywords: POT1; genome instability; telomeres; telomeropathies.

PubMed Disclaimer

References

REFERENCES

    1. Adam, M. P., Ardinger, H. H., Pagon, R. A., Wallace, S. E., Bean, L. J. H., Mirzaa, G., & Amemiya, A. (1993). POT1 tumor predisposition. In J. O. Marie-Louise Henry & T. obias Else (Eds.), GeneReviews® [Internet]. University of Washington, Seattle.
    1. Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., Baboud, J., Balasundaram, M., Balu, S., Barnabas, N., Bartlett, J., Bartlett, P., Bastian, B. C., Baylin, S. B., Behera, M., … Kwong, L. N. (2015). Genomic classification of Cutaneous Melanoma. Cell, 161(7), 1681-1696. https://doi.org/10.1016/j.cell.2015.05.044
    1. Akıncılar, S. C., Chua, J. Y. H., Ng, Q. F., Chan, C. H. T., Eslami-S, Z., Chen, K., Low, J. L., Arumugam, S., Aswad, L., Chua, C., Tan, I. B., DasGupta, R., Fullwood, M. J., & Tergaonkar, V. (2023). Identification of mechanism of cancer-cell-specific reactivation of hTERT offers therapeutic opportunities for blocking telomerase specifically in human colorectal cancer. Nucleic Acids Research, 51(1), 1-16. https://doi.org/10.1093/nar/gkac479
    1. Akıncılar, S. C., Low, K. C., Liu, C. Y., Yan, T. D., Oji, A., Ikawa, M., Li, S., & Tergaonkar, V. (2015). Quantitative assessment of telomerase components in cancer cell lines. FEBS Letters, 589(9), 974-984. https://doi.org/10.1016/j.febslet.2015.02.035
    1. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A. L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., … Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500(7463), 415-421. https://doi.org/10.1038/nature12477

Publication types

LinkOut - more resources